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Abstract: 
Background—Vascular occlusion and complex plexiform lesions are hallmarks of the pathology 
of severe pulmonary arterial hypertension (PAH) in patients. However, mechanisms of 
obliterative vascular remodeling remain elusive and hence current therapies have not targeted the 
fundamental disease modifying mechanisms and result in only modest improvement in morbidity 
and mortality. 
Methods and Results—Mice with Tie2Cre-mediated disruption of Egln1 (encoding prolyl-4 
hydroxylase 2, PHD2) (Egln1Tie2) in endothelial cells (ECs) and hematopoietic cells exhibited 
spontaneous severe PAH with extensive pulmonary vascular remodeling including vascular 
occlusion and plexiform-like lesions resembling the hallmarks of the pathology of clinical PAH. 
As seen in idiopathic PAH patients, Egln1Tie2 mice exhibited unprecedented right ventricular 
hypertrophy and failure and progressive mortality. Consistently, PHD2 expression was 
diminished in lung ECs of obliterated pulmonary vessels in idiopathic PAH patients. Genetic 
deletions of both Egln1 and Hif1a or Egln1 and Hif2a identified hypoxia-inducible factor-2? 
(HIF-2?) as the critical mediator of severe PAH seen in Egln1Tie2 mice. We also observed altered 
expression of many PH-causing genes in Egln1Tie2 lungs which was also normalized in 
Egln1Tie2/Hif2aTie2 lungs. PHD2-deficient ECs promoted smooth muscle cell proliferation in part 
through HIF-2?-activated CXCL12 expression. Genetic deletion of Cxcl12 attenuated PAH in 
Egln1Tie2 mice. 
Conclusions—These studies defined an unexpected role of PHD2 deficiency in the mechanisms 
of severe PAH and identified the first genetically modified mouse model with obliterative 
vascular remodeling and pathophysiology recapitulating clinical PAH. Thus, targeting 
PHD2/HIF-2? signaling is a promising strategy to reverse vascular remodeling for treatment of 
severe PAH.  
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Introduction 
Pulmonary arterial hypertension (PAH) is characterized by progressive increase of pulmonary 
vascular resistance and obliterative pulmonary vascular remodeling that result in right heart 
hypertrophy, failure and premature death. 1 The histopathological features of PAH includes 
intima and media thickness, muscularization of distal pulmonary arteries, vascular occlusion and 
complex plexiform lesions. 2-5 Owing to the poor understanding of the underlying mechanisms of 
obliterative vascular remodeling, current therapies targeting abnormalities in the prostacyclin, 
nitric oxide, and endothelin pathways result in only modest improvement in morbidity and 
mortality. 6-8 One of the major hurdles is the lack of appropriate murine models recapitulating the 
pathophysiology of severe PAH in patients including idiopathic PAH (IPAH). 9,10 Thus, 
identifying such genetically modified mouse model(s) and elucidating the molecular mechanisms 
of obliterative pulmonary vascular remodeling will provide valuable druggable targets and novel 
therapeutic approaches for effective treatment of PAH in patients. 
Hypoxia-inducible factors (HIFs) comprised of an O2-sensitive ?-subunit (mainly HIF-
1? and HIF-2?) and a constitutively expressed ?-subunit are key transcription factors mediating 
adaptive responses to hypoxia and ischemia. 11,12 As O2 sensors, HIF prolyl-4 hydroxylases 
[prolyl hydroxylase domain-containing enzymes (PHDs), also known as EGLN1-3] use 
molecular O2 as a substrate to hydroxylate specific proline residues of HIF-?. Hydroxylation 
promotes HIF-? binding to the von Hippel-Lindau (VHL) ubiquitin E3 ligase resulting in 
ubiquitination and subsequent degradation by proteasome. 13-16 Under hypoxic condition, 
inhibited PHD activity results in stabilization and accumulation of HIF-? in the nucleus. HIF-? 
and HIF-? form a heterodimer and activate expression of target genes that regulate angiogenesis, 
erythropoiesis, metabolism, inflammation, and vascular responses 11, 12, 17. It has been shown that 
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HIF-? activation plays an important role in the pathogenesis of pulmonary hypertension (PH). 
Hif1a+/- mice exhibited decreased PH whereas Hif2a+/- mice fail to develop PH in response to 
chronic hypoxia.18, 19 Inactivation of Hif1a in smooth muscle cells (SMCs) in adult also 
attenuates hypoxia-induced PH. 20 An activating mutation of Hif2a induces PAH in mice and 
humans.21,22 Vhl mutation also induces PH in mice and humans. 23,24 However, little is known 
about the role of PHDs in the pathogenesis of PH. Pharmacological and genetic evidence showed 
that PHD2 is responsible for the majority of HIF-? hydroxylation while PHD1 and PHD3 play 
compensatory roles under certain conditions.25-30 Mice with inactivation of PHD2 are embryonic 
lethal whereas PHD1 or PHD3 deficient mice are viable and normal.27,28 siRNA-mediated 
knockdown of PHD2, but not PHD1 or PHD3, leads to HIF stabilization in cell culture.25 Thus, 
we set to determine the fundamental role of PHD2 in regulating pulmonary vascular remodeling 
and the pathogenesis of severe PAH. We observed that PHD2 expression was diminished in 
endothelial cells (ECs) of obliterative pulmonary vessels of IPAH patients. Employing the mice 
with Tie2Cre-mediated disruption of Egln1 (encoding PHD2) in ECs and hematopoietic cells 
(HCs) (Egln1Tie2), we observed spontaneous severe PAH with extensive pulmonary vascular 
remodeling including vascular occlusion and plexiform-like lesions, and severe right ventricular 
(RV) hypertrophy and right-sided heart failure. This phenotype is strikingly different from PH in 
mice induced by hypoxia alone or hypoxia and Sugen 5416 treatment.17, 31-33 To the best of our 
knowledge, this is the first mouse model with irreversible obliterative vascular remodeling and 
pathophysiology as seen in patients with severe PAH including IPAH.9,10, 32,33 We identified 
HIF-2?(not HIF-1?) activation as the critical mediator of severe PAH downstream of PHD2 
deficiency. We also showed that HIF-2?-mediated expression of CXCL12 (also known as 
stromal cell-derived factor 1?, SDF-1?) in PHD2-deficient ECs promoted pulmonary arterial 
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SMC proliferation and contributed to the pathogenesis of severe PAH in Egln1Tie2 mice.  
 
Methods 
Mice 
To generate Egln1Tie2 mice, Egln1 floxed mice28 were bred with Tie2 promoter/enhancer- driven 
Cre transgenic mice.34 Egln1Tie2/Hif1aTie2 (EH1) and Egln1Tie2/Hif2aTie2 (EH2) mice were 
generated by breeding Hif1a or Hif2a floxed mice with Egln1Tie2 mice. Egln1Tie2/Cxcl12Tie2 
(ECx) mice were generated by breeding Cxcl12 floxed mice with Egln1Tie2 mice. All breeder 
mice were purchased from the Jackson Laboratory and littermate WT mice were used as 
controls. Both male and female mice were used for the experiments. The experiments were 
conducted according to NIH guidelines on the use of laboratory animals. The animal care and 
study protocol was approved by the Institutional Animal Care and Use Committee of the 
University of Illinois at Chicago. 
Human subjects 
Human lung tissues were obtained from patients undergoing lung transplantation for IPAH and 
from unused donor lungs. Informed consent from patients and local ethical approval from the 
ethics committees of the Hammersmith Hospitals (ref. no. 2001/6003) and Royal Brompton & 
Harefield Hospitals (ref. no. 01-210) were obtained prior to tissue collection. 35 
Statistical analysis 
Statistical significance was determined by one-way or two-way ANOVA with a Games-Howell 
post hoc analysis that calculates P values corrected for multiple comparisons. Two- group 
comparisons were analyzed by the unpaired two-tailed Student's t test for equal variance or 
Welch t test for unequal variance. Statistical analysis of the mortality study was performed with 
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the Log–rank (Mantel-Cox) test. P < 0.05 denoted the presence of a statistically significant 
difference. All bar graphs represent mean ± SD. An expanded Materials and Methods section 
containing detailed description of echocardiography, RV hemodynamic measurement, bone 
marrow transplantation, histology and immunostaining, primary culture of human lung 
microvascular ECs and pulmonary arterial SMCs, siRNA-mediated knockdown, molecular 
analysis, RNA sequencing and bioinformatics analysis is provided in the online-only Data 
Supplement. 
 
Results 
Loss of PHD2 in endothelial cells and hematopoietic cells induces severe PAH and right 
heart hypertrophy and failure 
To gain insight into the role of PHD2 in the pathogenesis of PAH, we inactivated PHD2 in the 
mouse endothelium. Mice carrying an Egln1 gene in which exons 2 and 3 were flanked by 2 loxP 
sites were bred with Tie2 promoter/enhancer-driven Cre (Tie2Cre) transgenic mice to generate 
mice with Tie2Cre-mediated disruption of Egln1 (Egln1Tie2) (Figure 1A). Western blotting 
analysis showed that PHD2 expression was reduced greater than 90% in lung ECs of Egln1Tie2 
mice (Figure 1B). Quantitative real-time RT-PCR (QRT-PCR) also revealed selective deletion 
of PHD2 in lung ECs but not fibroblasts (Figure 1C). Immunostaining demonstrated diminished 
PHD2 expression in pulmonary vascular ECs but not in bronchial epithelial cells in Egln1Tie2 
mice (Figure 1D). Together, these data demonstrate EC-specific deletion of PHD2 in Egln1Tie2 
mouse lungs. Immunostaining also showed loss of PHD2 expression in aortic ECs of Egln1Tie2 
mice (Supplemental Figure 1). Egln1Tie2 mice were born normally in a Mendelian ratio. To 
determine whether these mutant mice develop PAH, we measured right-ventricular systolic 
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pressure (RVSP), which reflects PA systolic pressure. Egln1Tie2 mice had dramatically elevated 
RVSP that ranged from 60-90 mmHg in mice aged 3.5 months (Figure 1, E and F). 
However, systemic blood pressure was normal (Supplemental Figure 1). Egln1Tie2 mice also 
developed pronounced RV hypertrophy evident by the drastic increase of the weight ratio of 
right/left ventricle plus septum (RV/LV+S) which averaged 0.9, a value not seen in other mouse 
PH models (Figure 1G). 
Given that PAH induces RV hypertrophy and heart failure, we performed 
echocardiography to evaluate cardiac size and function in vivo. The RV chamber was markedly 
enlarged in Egln1Tie2 mice whereas barely evident in WT mice (Figure 2, A and B). Egln1Tie2 
mice exhibited marked RV hypertrophy as evidenced by a 3-fold increase in RV wall thickness 
(Figure 2C), and decreased RV contractility (Figure 2D). However, the LV cardiac size and 
function of Egln1Tie2 mice were similar to those of WT mice (Supplemental Figure 2), 
suggesting that PAH in Egln1Tie2 mice is not secondary to LV dysfunction. Egln1Tie2 mice also 
exhibited a decreased ratio of PA acceleration time/ejection time (PA AT/ET) (Figure 2E), 
indicating PA diastolic dysfunction. To determine whether Egln1Tie2 mice develop right-sided 
heart failure, we assessed expression of molecular markers of heart failure.36, 37 QRT-PCR 
analysis revealed a marked increase of expression of atrial natriuretic factor and skeletal ?-actin 
(Figure 2F). Reactivation of this embryonic gene program is a common feature of heart failure. 
As seen in IPAH patients, Egln1Tie2 mice also exhibited progressive mortality; 80% of Egln1Tie2 
mice died by the age of 6 months (Figure 2G). These findings demonstrate that Egln1Tie2 mice 
develop spontaneous severe PAH which results in RV failure and premature death as seen in the 
clinical setting. 
Because Tie2Cre also induces gene deletion in hematopoietic cells (HCs) besides 
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ECs,38,39 we next determined the contribution of PHD2-deficient HCs. We transplanted 
Egln1Tie2 bone marrow cells to lethally irradiated WT mice (WT chimeric mice) and WT bone 
marrow cells to lethally irradiated Egln1Tie2 mice (Egln1Tie2 chimeric mice). As shown in Figure 
3, WT chimeric mice reconstituted with Egln1Tie2 bone marrow cells did not show evidence of 
PAH with normal RVSP and RV/(LV+S) ratio. However, Egln1Tie2 chimeric mice reconstituted 
with WT bone marrow cells had decreased RVSP and RV/(LV+S) ratio compared to Egln1Tie2 
mice. Pulmonary vascular remodeling including adventitial and intimal but not medial thickness 
in Egln1Tie2 chimeric mice was also attenuated (Supplemental Figure 3). These data suggest 
that endothelial PHD2 deficiency is essential for induction of PAH whereas PHD2 deletion in 
HCs promotes the severity of PAH. 
Obliterative pulmonary vascular remodeling in Egln1Tie2 mice 
To further compare the similarities between the Egln1Tie2 mouse phenotype and clinical PAH, we 
examined pulmonary pathology. Lung sections from Egln1Tie2 mice (3.5 mo old) showed various 
forms of vascular remodeling, including pulmonary arterial intima, medial and adventitial 
thickness, occlusive intima and plexiform-like lesions (Figure 4, A and B and Supplemental 
Figure 4). Occlusion was observed in both large and small pulmonary arteries (Figure 4A and 
Supplemental Figure 4). Anti-CD31 (marker for ECs) immunohistochemistry revealed strong 
CD31 staining in ECs of pulmonary vessels without complete occlusion (Figure 4B and 
Supplemental Figure 4, I and J) but diminished in completely occluded vessels (Supplemental 
Figure 4, I and J). Intriguingly, multi-CD31+ channels were evident in the adventitial of some 
severely remodeled pulmonary vessels (Figure 4B). Histological quantification revealed more 
severe pulmonary vascular remodeling in Egln1Tie2 mice at age of 3.5 mo compared to age of 1.5 
mo. In Egln1Tie2 mice aged 3.5 mo, 16% of the vessels were occlusive and 8% of large vessels 
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(>100 μm diameter) exhibited plexiform-like lesions including lesions with multi-CD31+ 
channels (Figure 4C). Prominent immunostaining of smooth muscle ?-actin was evident in 
theses lesions (Figure 4D). Immunostatining with anti-FSP1 (marker for fibroblasts) or anti-
CD11b (marker for monocytes) demonstrated the adventitial of these lesions was fibroblast-
enriched whereas fewer CD11b-positive monocytes (Figure4, E and F). 
Increased cell proliferation in pulmonary vascular lesions in Egln1Tie2 mice 
We next determined whether vascular occlusion and formation of plexiform-like lesions in 
Egln1Tie2 lungs was associated with abnormal vascular cell proliferation. Mouse lung sections 
were immunostained with anti-Ki67, a marker for cell proliferation and anti-CD31 for ECs. As 
shown in Figure 4G, Ki67 staining was observed in pulmonary vascular ECs, SMCs as well as 
adventitial cells in Egln1Tie2 lungs but not evident in control WT lung sections. Furthermore, 
Western blotting demonstrated a marked increase of expression of proliferating cell nuclear 
antigen (PCNA), a marker for cell proliferation in Egln1Tie2 lung tissues (Figure 4H). 
Diminished expression of PHD2 in ECs of occlusive pulmonary vessels in IPAH patients 
To further determine the clinical relevance of our observations in Egln1Tie2 mice, we assessed 
PHD2 expression in lung sections from IPAH patients and normal donors.35 PHD2 expression 
was diminished in the lumen (ECs) of occlusive pulmonary vessels of IPAH patients (Figure 5). 
However, non-occlusive pulmonary vessels from the same patients exhibited relatively normal 
PHD2 expression as seen in the control samples (Figure 5). These data suggest an important role 
for PHD2 deficiency in pulmonary vascular ECs in mediating obliterative vascular remodeling in 
patients. 
HIF-2? activation secondary to PHD2 deficiency mediates PAH in Egln1Tie2 mice 
To determine the molecular basis of severe PAH in Egln1Tie2 mice, we first analyzed HIF- 1? 
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and HIF-2? protein expression. Both proteins were markedly increased in Egln1Tie2 lungs, a 
result consistent with PHD2 deficiency-induced stabilization (Figure 6A). We then generated 
Egln1Tie2/Hif1aTie2 (EH1) and Egln1Tie2/Hif2aTie2 (EH2) double knockout mice by breeding Hif1a 
or Hif2a floxed mice with Egln1Tie2 mice (Figure 6B). The RVSP and the RV/LV+S ratio in 
EH2 mice were completely normal (Figure 6, C and D, and Supplemental Figure 5), whereas 
EH1 mice exhibited similar changes to those in Egln1Tie2 mice (Figure 6, C and D). 
Echocardiography also revealed normal RV wall thickness indicating no hypertrophy, as well as 
normal PA diastolic function evident by normal value of AT/ET ratio in EH2 mice (Figure 6, E 
and F). EH2 mice at 3.5 mo of age also exhibited normal pulmonary vascular pathology without 
evidence of vascular wall thickening, occlusion, or muscularization of the distal pulmonary 
arteries (Figure 6, G-I). These data demonstrate that activation of HIF-2? (not HIF-1?) 
secondary to PHD2 deficiency is responsible for the obliterative vascular remodeling and severe 
PAH in Egln1Tie2 mice. 
Altered expression of PH-causing genes in Egln1Tie2 lungs and normalization in EH2 lungs 
To delineate the molecular signaling events that contribute to the severe PAH phenotype of 
Egln1Tie2 mice downstream of HIF-2?, we performed whole transcriptome RNA sequencing 
(RNA-seq) analysis (Figure 7, A-E). RNA-seq data analysis showed up-regulation of HIF-? 
target genes in Egln1Tie2 lung, consistent with activation of HIF-?. Expression of some of them 
such as Arg1, Egln3, Serpine1, pak6, Il6, Lox, and Nov was completely normalized in EH2 lungs, 
suggesting these are HIF-2? target genes in Egln1Tie2 lungs (Figure 7B). We also analyzed the 
expression profiles of genes involved in the pathogenesis of PH. Genes shown upregulated in 
various animal models of PH was markedly induced in Egln1Tie2 lungs. Expression of these 
genes was normalized in EH2 lungs (Figure 7C). Expression of genes known downregulated in 
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published PH models was decreased in Egln1Tie2 lungs and restored to levels either similar to or 
greater than WT lungs in EH2 mice (Figure 7, D and E). QRT-PCR analysis confirmed marked 
changes of expression of these genes in Egln1Tie2 lungs, including increased expression of 
Slc39a12, Eln, Sphk1, Csf2, Cxcl12, Il6, and Edn1 and decreased expression of Ccr7, Apln, 
Aplnr, Cav1, Prkg1, Ccr2, and Bmpr2. Expression of these genes was normalized in EH2 lungs 
(Figure 7, F and G). These data suggest the complex pathology and severe PAH in Egln1Tie2 
mice are attributable to dysregulation of multiple signaling pathways secondary to PHD2 
deficiency-activated HIF-2?. 
PHD2-deficient ECs induces pulmonary arterial SMC proliferation partially through HIF- 
2?-dependent release of CXCL12 
Given that pulmonary arterial SMC proliferation plays an important role in pulmonary vascular 
remodeling, we next determined the role of PHD2 deficiency in ECs in directing pulmonary 
arterial SMC proliferation. Employing a co-culture Transwell system, human lung microvascular 
ECs deficient in PHD2 induced by PHD2 siRNA-mediated knockdown (Figure 8A) were plated 
in the top chamber while human pulmonary arterial SMCs were cultured in the bottom chamber. 
As shown in Figure 8, B and C, PHD2-deficient ECs induced a marked increase of SMC 
proliferation, suggesting PHD2-deficient ECs play an important role in pulmonary vascular 
remodeling by directly releasing factor(s) to activate SMC proliferation. 
We next explored the role of CXCL12 released by PHD2-deficient ECs in promoting 
SMC proliferation. As shown in Figure 8A, siRNA-mediated knockdown of PHD2 in human 
lung microvascular ECs induced a five-fold increase of expression of CXCL12. HIF-2? siRNA- 
mediated knockdown of HIF-2? inhibited PHD2 deficiency-induced CXCL12 expression 
whereas HIF-1? knockdown had no effect, demonstrating CXCL12 is a HIF-2? but not HIF-1? 
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target gene in PHD2-deficient lung ECs. To determine whether induced CXCL12 expression 
contributes to SMC proliferation, we employed siRNA to knockdown CXCL12 in PHD2- 
deficient ECs (Figure 8D). Co-culture experiment demonstrated knockdown of CXCL12 in 
PHD2-deficient ECs resulted in a marked decrease of SMC proliferation (Figure 8, B and C), 
suggesting CXCL12 is one of the factors released from PHD2-defieicnt ECs promoting SMC 
proliferation. 
PHD2/HIF-2?-dependent activation of CXCL12 signaling contributes to the pathogenesis 
of severe PAH in Egln1Tie2 mice 
In Egln1Tie2 lungs, we also observed a marked increase of CXCL12 expression compared to WT 
lungs which was inhibited in EH2 lungs but not in EH1 lungs (Figure 8E), consistent with our 
observation in PHD2-deficient ECs described above. Thus, we generated a double knockout 
mouse model with genetic deletions of both Egln1 and Cxcl12 by breeding Cxcl12 floxed mice 
into the genetic background of Egln1Tie2 mice (Figure 8F). RVSP measurement revealed a 
marked decrease of PAH in Egln1Tie2/Cxcl12Tie2 mice compared to Egln1Tie2 mice (Figure 8G). 
RV hypertrophy was also markedly attenuated in these double knockout mice (Figure 8H). 
Together, these data demonstrate that HIF-2?-dependent activation of CXCL12 signaling 
contributes to the pathogenesis of severe PAH in Egln1Tie2 mice (Figure 8I). 
 
Discussion 
The present study has demonstrated for the first time that genetic deletion of Egln1 in ECs and 
HCs induces spontaneous progressive PAH with severe vascular remodeling including occlusion 
and complex plexiform-like lesions that resemble the pathology of clinical PAH. As seen in 
IPAH patients, Egln1Tie2 mice exhibit severe RV hypertrophy and failure and thereby progressive 
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mortality. We also observed dysregulated expression of multiple PH-causing genes in Egln1Tie2 
lungs, and demonstrated that CXCL12 induced in PHD2-deficient ECs promoted SMC 
proliferation. Inhibition of CXCL12 by Tie2Cre-mediated genetic deletion attenuated PAH in 
Egln1Tie2 mice. These complex pathological and molecular changes in Egln1Tie2 lungs are 
ascribed to HIF-2? activation. The observation that PHD2 expression is diminished in ECs of 
obliterative pulmonary vessels of IPAH patients further demonstrates the clinical relevance of 
this model. These findings may lead to novel therapeutic strategies for the treatment of severe 
PAH including IPAH in patients. 
Vascular occlusion and complex plexiform lesions are hallmarks of the pathology of 
severe PAH in patients. Although PAH in rats treated with vascular endothelial growth factor 
receptor inhibitor Sugen 5416 and chronic hypoxia shows severe pulmonary vascular remodeling 
with stable vascular occlusion and plexiform-like lesions,40,41 obliterative vascular lesions in 
lungs of hypoxia/Sugen 5416-treated mice are not stable and resolved after 10 weeks of 
normoxic exposure.33 A recent study also shows occlusive lung arterial lesions in a transgenic 
mouse model with inducible EC apoptosis.42 However, the majority of these transgenic mice 
exhibit normal lung phenotype and only a small proportion (21%) of them develop mild PAH 
with scarce occlusive lesions. Other genetically modified mouse models don’t exhibit such 
complex vascular lesions.9,10 RV hypertrophy is in general mild to median (RV/LV+S ratio = 
0.3-0.5) in these alternative mouse models. Thus, there is no PAH mouse model that 
recapitulates the complex pathology of clinical PAH in the literature.9,10 Our study provides 
unequivocal evidence that Tie2Cre-mediated disruption of Egln1 induces spontaneous severe 
PAH with characteristics of irreversible vascular occlusion and plexiform-like lesions. These 
mice exhibit marked increase of RVSP ranging from 60-90 mmHg and unprecedented RV 
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hypertrophy with RV/LV+S ratio averaged at 0.9. To the best of our knowledge, this is the first 
mouse model showing such great increases of RVSP and severe RV hypertrophy. Consistent 
with the progressive mortality seen in IPAH patients, these mice also exhibit progressive 
mortality and 80% of them die by age of 6 months. It is likely that these mice die of right heart 
failure as they exhibit severe RV hypertrophy, decreased RV contractility, and reactivation of an 
embryonic gene program in the RV, a common feature of human heart failure.36 Intriguingly, 
Egln1Tie2 mice also exhibit altered expression of many genes involved in the pathogenesis of PH. 
Among the 21 genes validated by QRT-PCR analysis, 18 genes are dysregulated in Egln1Tie2 
lungs. Together, these data demonstrate the first mouse model recapitulating the pathogenesis of 
clinical PAH. Additionally, PHD2 expression is diminished in ECs of obliterative pulmonary 
vessels in IPAH patients, further demonstrating the clinical relevance of this model. 
It is well known that hypoxia and HIF signaling play an important role in the 
pathogenesis of PH. Unexpectedly, we show spontaneous severe PAH with complex pulmonary 
vascular remodeling in Egln1Tie2 mice. The severity and complexity of the pulmonary phenotype 
have not been reported in mouse models induced by either hypoxia or hypoxia/Sugen 5416 or 
genetic modifications of other HIF signaling molecules. Egln1Tie2 mice have much more severe 
PAH phenotype than either VhlR200W mutation mice or Hif2aG536W knockin mice (average RVSP: 
Egln1Tie2 mice at age of 3.5 months, 70 mmHg; Hif2aG536W knockin mice at 4-6 months age, 
42mmHg). There are no occlusive lesions but only slight increase of small pulmonary arterial 
thickness in VhlR200W mutation mice or Hif2aG536W knockin mice.22, 24 Intriguingly, the severe 
PAH phenotype in Egln1Tie2 mice is ascribed to activation of HIF-2? but not HIF-1?. Both 
pathological and molecular changes in Egln1Tie2 mice are normalized by genetic deletion of 
Hif2a. Consistent with our observation, previous studies have shown that heterozygous Hif2? 
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deletion partially rescues VhlR200W mutation-induced PAH.24 Together, these studies point out an 
obligatory role of HIF-2? activation in the pathogenesis of PAH. Although HIF-1? and HIF-2? 
bind to an identical core sequence in hypoxia response element, they can activate distinct sets of 
genes.43 Data from our RNA sequencing analysis show expression of some of the HIF-? target 
genes are dysregulated in Egln1Tie2 mouse lungs but normalized by Hif2a deletion, suggesting 
these are HIF-2? target genes whereas a couple of them such as Bnip3 and Pgk1 are more likely 
HIF-1? target genes. In human lung ECs, our data demonstrate CXCL12 as a target gene of HIF- 
2?. Additionally, HIF-2? is predominantly expressed in ECs whereas HIF-1? is more 
ubiquitously expressed almost in all cell types.44 Thus, HIF-2? may function differently than 
HIF-1? under various (patho) physiological conditions. 
Pulmonary endothelial dysfunction has been identified as a critical mediator of 
pulmonary vascular remodeling. Our co-culture study provides clear evidence that PHD2-
deficient ECs directly induce SMC proliferation, indicating the importance of endothelial 
crosstalk with SMCs in the mechanisms of pulmonary vascular remodeling. We have identified 
CXCL12 as one of the factors released from PHD2-deficient ECs to induce SMC proliferation. 
The partial inhibition of SMC proliferation by CXCL12 knockdown in PHD2-deficient ECs 
suggest other angiogenic factor(s) also contribute to EC-induced SMC proliferation. Consistent 
with our observation in vitro, genetic deletion of Cxcl12 results in marked decrease of PAH in 
Egln1Tie2 mice. Our data from RNA sequencing as well as QRT-PCR analysis demonstrate 
dysregulation of many PH- causing genes including Edn1 (encoding Endothelin-1) and Prkg1 
(encoding protein kinase G) in Egln1Tie2 lungs. Thus, it is unlikely to completely rescue the 
hypertensive pulmonary phenotype in Egln1Tie2 mice by targeting one specific pathway 
downstream of PHD2/HIF-2? signaling. 
 at Imperial College London Library on May 12, 2016http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.116.021494 
16 
These data also suggest the importance of combination therapy in treatment of PAH in 
patients.45 Another surprising finding is that PHD2 deficiency induced severe PAH but had no 
effects on systemic pressure. These differential effects of PHD2 deficiency are likely due to the 
marked difference of expression of PHD2 in the pulmonary vasculature compared to the 
systemic vasculature. PHD2 is highly expressed in pulmonary vascular ECs but much weakly in 
systemic vascular ECs. Accordingly, PHD2 deficiency-induced expression of Cxcl12 and 
Endothelin-1 in pulmonary vascular ECs and Egln1Tie2 mouse lungs was not seen in Egln1Tie2 
mouse aorta. 
Besides the role Cxcl12 in the development of severe PAH in Egln1Tie2 mice, Endothelin-1 is a 
potent vasoconstrictor and clinical studies have demonstrated its role in the pathogenesis of 
PAH. Together, these data provide clear evidence about the differential effects of PHD2 
deficiency on the pulmonary vascular system and the systemic vasculature. 
Our studies also demonstrate an important role of PHD2 deficiency in HCs in mediating 
the severe PAH phenotypes in Egln1Tie2 mice. On one hand, WT chimeric mice reconstituted 
with Egln1Tie2 bone marrow cells fail to develop PAH, indicating PHD2 deficiency in bone 
marrow cells is not a prerequisite condition for the development of PAH. On the other hand, 
reconstitution of WT bone marrow cells in lethally irradiated Egln1Tie2 mice attenuates PAH, 
indicating Tie2Cre-meidated disruption of PHD2 in HCs contributes to the severity of PAH. 
These transplanted chimera experiments demonstrate the synergistic contribution of both 
endothelial and hematopoietic PHD2 deficiency to the severe PAH phenotype and complex 
pathology seen in Egln1Tie2 mice. Prior studies also demonstrate an important role of bone 
marrow abnormality associated with altered HIF signaling in the pathogenesis of clinical 
PAH.46,47 In addition, accumulating evidence shows that macrophages, T cells, and progenitor 
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cells are recruited in the lesions contributing to vascular remodeling.47-49 It has also been shown 
that HIF- stimulated extracellular adenosine production and signaling affect the pathogenesis of 
PH through modulation of macrophage functional polarization50. Given the observation of 
induced CXCL12 expression in PHD2-deficient ECs, PHD2 deficiency in ECs may also promote 
bone marrow cell recruitment to the lung and thereby induces complex vascular remodeling. 
Thus, future studies are warranted to determine which bone marrow cell population(s) contribute 
to the severe PAH phenotype in Egln1Tie2 mice and whether PHD2-deficient EC-released 
CXCL12 and/or other chemokine(s) promote bone marrow cell recruitment and thereby 
contributing to the severity of PAH. 
In summary, we have demonstrated for the first time that genetic deletion of Egln1 in 
ECs and HCs induces spontaneous progressive PAH with severe vascular remodeling including 
occlusion and complex plexiform-like lesions and pronounced RV hypertrophy and RV failure 
that resemble the pathology of clinical PAH. We also identify HIF-2? as a critical mediator of 
severe PAH seen in Egln1Tie2 mice. The severe PAH phenotype characterized with complex 
obliterative vascular remodeling and dysregulation of various signaling pathways as seen in 
clinical PAH makes the Egln1Tie2 mouse an unique and potentially useful mouse model for 
delineating the molecular mechanisms underlying the complex vascular remodeling of clinical 
PAH. Thus, targeting dysregulated PHD2-HIF-2? signaling may represent a novel effective 
therapeutic strategy to inhibit pulmonary vascular remodeling for the treatment of severe PAH, 
including IPAH and thereby promote survival. 
 
Funding Sources: This work was supported in part by NIH grants R01HL123957, 
R01HL125350, and P01HL077806 (Project 3) to Y.Y. Z and American Heart Association 
postdoctoral fellowship grant 15POST25700124 to Z.D. 
 at Imperial College London Library on May 12, 2016http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.116.021494 
18 
Conflict of Interest Disclosures: None. 
 
References: 
 
1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, 
McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, 
Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs 
AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson 
RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ, ACCF/AHA. 
ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the 
American College of Cardiology Foundation Task Force on Expert Consensus Documents and 
the American Heart Association: developed in collaboration with the American College of Chest 
Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. 
Circulation. 2009;119:2250-2294. 
 
2. Voelkel NF, Cool C. Pathology of pulmonary hypertension. Cardiol Clin. 2004;22:343-351, v. 
 
3. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. 
Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 
2004;43:25S-32S. 
 
4. Meyrick B. The pathology of pulmonary artery hypertension. Clin Chest Med. 2001;22:393-
404, vii. 
 
5. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, 
Grizzle WE, Aldred MA, Cool CD, Tuder RM. Modern age pathology of pulmonary arterial 
hypertension. Am J Respir Crit Care Med. 2012;186:261-272. 
 
6. Farber HW. The status of pulmonary arterial hypertension in 2008. Circulation. 
2008;117:2966-2968. 
 
7. Sutendra G, Michelakis ED. Pulmonary arterial hypertension: challenges in translational 
research and a vision for change. Sci Transl Med. 2013;5:208sr5. 
 
8. McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial 
hypertension. J Am Coll Cardiol. 2015;65:1976-1997. 
 
9. Ryan JJ, Marsboom G, Archer SL. Rodent models of group 1 pulmonary hypertension. Handb 
Exp Pharmacol. 2013;218:105-149. 
 
10. Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, Taraseviciene- 
Stewart L, Sung Y, Kraskauskas D, Farkas D, Conrad DH, Nicolls MR, Voelkel NF. A brief 
overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J 
Physiol Lung Cell Mol Physiol. 2012;302:L977-991. 
 
 at Imperial College London Library on May 12, 2016http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.116.021494 
19 
11. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to 
hypoxic stress. Mol Cell. 2010;40:294-309. 
 
12. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148:399-
408. 
 
13. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, 
Kaelin WG,Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: 
implications for O2 sensing. Science. 2001;292:464-468. 
 
14. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, 
Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, 
Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and 
mammalian homologs define a family of dioxygenases that regulate HIF by prolyl 
hydroxylation. Cell. 2001;107:43-54. 
 
15. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, 
Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of 
HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl 
hydroxylation. Science. 2001;292:468-472. 
16. Bishop T, Ratcliffe PJ. HIF hydroxylase pathways in cardiovascular physiology and 
medicine. Circ Res. 2015;117:65-79. 
 
17. Shimoda LA, Semenza GL. HIF and the lung: role of hypoxia-inducible factors in pulmonary 
development and disease. Am J Respir Crit Care Med. 2011;183:152-156. 
 
18.Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener 
CM, Sylvester JT, Semenza GL. Impaired physiological responses to chronic hypoxia in mice 
partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest. 1999;103:691-696. 
 
19. Brusselmans K, Compernolle V, Tjwa M, Wiesener MS, Maxwell PH, Collen D, Carmeliet 
P. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary 
hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest. 
2003;111:1519-1527. 
 
20. Ball MK, Waypa GB, Mungai PT, Nielsen JM, Czech L, Dudley VJ, Beussink L, Dettman 
RW, Berkelhamer SK, Steinhorn RH, Shah SJ, Schumacker PT. Regulation of hypoxia-induced 
pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1alpha. Am J 
Respir Crit Care Med. 2014;189:314-324. 
21. Gale DP, Harten SK, Reid CD, Tuddenham EG, Maxwell PH. Autosomal dominant 
erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha 
mutation. Blood. 2008;112:919-921. 
 
22. Tan Q, Kerestes H, Percy MJ, Pietrofesa R, Chen L, Khurana TS, Christofidou-Solomidou 
 at Imperial College London Library on May 12, 2016http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.116.021494 
20 
M, Lappin TR, Lee FS. Erythrocytosis and pulmonary hypertension in a mouse model of human 
HIF2A gain of function mutation. J Biol Chem. 2013;288:17134-17144. 
 
23. Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, Liu C, Maxwell 
PH, McMullin MF, McNamara CJ, Percy MJ, Pugh CW, Ratcliffe PJ, Talbot NP, Treacy M, 
Robbins PA. Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary 
physiology. PLoS Med. 2006;3:e290. 
 
24. Hickey MM, Richardson T, Wang T, Mosqueira M, Arguiri E, Yu H, Yu QC, Solomides CC, 
Morrisey EE, Khurana TS, Christofidou-Solomidou M, Simon MC. The von Hippel-Lindau 
Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest. 
2010;120:827-839. 
 
25. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 
is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 
2003;22:4082-4090. 
26. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle 
JM. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of 
hypoxia-inducible factor. J Biol Chem. 2004;279:38458-38465. 
27. Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A, Fong GH. Placental but not heart defects 
are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl 
hydroxylase domain protein 2. Mol Cell Biol. 2006;26:8336-8346. 
 
28. Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG,Jr. Somatic 
inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. 
Blood. 2008;111:3236-3244. 
 
29. Takeda K, Cowan A, Fong GH. Essential role for prolyl hydroxylase domain protein 2 in 
oxygen homeostasis of the adult vascular system. Circulation. 2007;116:774-781. 
 
30. Walmsley SR, Chilvers ER, Thompson AA, Vaughan K, Marriott HM, Parker LC, Shaw G, 
Parmar S, Schneider M, Sabroe I, Dockrell DH, Milo M, Taylor CT, Johnson RS, Pugh CW, 
Ratcliffe PJ, Maxwell PH, Carmeliet P, Whyte MK. Prolyl hydroxylase 3 (PHD3) is essential for 
hypoxic regulation of neutrophilic inflammation in humans and mice. J Clin Invest. 
2011;121:1053-1063. 
 
31. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: 
cellular and molecular mechanisms. Circ Res. 2006;99:675-691. 
 
32. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, 
Morrell NW, Jarai G, Walker C, Westwick J, Thomas M. A novel murine model of severe 
pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;184:1171-1182. 
 
33. Vitali SH, Hansmann G, Rose C, Fernandez-Gonzalez A, Scheid A, Mitsialis SA, 
 at Imperial College London Library on May 12, 2016http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.116.021494 
21 
Kourembanas S. The Sugen 5416/hypoxia mouse model of pulmonary hypertension revisited: 
long-term follow-up. Pulm Circ. 2014;4:619-629. 
34. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. Tie2- 
Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol. 
2001;230:230-242. 
 
35. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Vogel SM, Brovkovych V, Yuan JX, 
Wharton J, Malik AB. Persistent eNOS activation secondary to caveolin-1 deficiency induces 
pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest. 
2009;119:2009-2018. 
 
36. Chien KR. Stress pathways and heart failure. Cell. 1999;98:555-558. 
 
37. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, Chu PH, Peterson K, Ross J,Jr, Chien 
KR. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in 
knockout mice. Proc Natl Acad Sci U S A. 2002;99:11375-11380. 
 
38. Constien R, Forde A, Liliensiek B, Grone HJ, Nawroth P, Hammerling G, Arnold B. 
Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated 
by a Tie2 Cre mouse line. Genesis. 2001;30:36-44. 
 
39. Koni PA, Joshi SK, Temann UA, Olson D, Burkly L, Flavell RA. Conditional vascular cell 
adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J Exp 
Med. 2001;193:741-754. 
40. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, 
Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia 
causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary 
hypertension. FASEB J. 2001;15:427-438. 
 
41. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. 
Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. 
Circulation. 2010;121:2747-2754. 
 
42. Goldthorpe H, Jiang JY, Taha M, Deng Y, Sinclair T, Ge CX, Jurasz P, Turksen K, Mei SH, 
Stewart DJ. Occlusive Lung Arterial Lesions in Endothelial-Targeted, Fas-Induced Apoptosis 
Transgenic Mice. Am J Respir Cell Mol Biol. 2015;53:712-718. 
 
43. Hu CJ, Sataur A, Wang L, Chen H, Simon MC. The N-terminal transactivation domain 
confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Mol Biol 
Cell. 2007;18:4528-4542. 
 
44. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, 
Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt 
KU. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of 
 at Imperial College London Library on May 12, 2016http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.116.021494 
22 
different organs. FASEB J. 2003;17:271-273. 
45. Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, 
Simonneau G, Vachiery JL, Grunig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, 
Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ, AMBITION Investigators. Initial Use of 
Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373:834- 
844. 
 
46. Farha S, Asosingh K, Xu W, Sharp J, George D, Comhair S, Park M, Tang WH, Loyd JE, 
Theil K, Tubbs R, Hsi E, Lichtin A, Erzurum SC. Hypoxia-inducible factors in human 
pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood. 
2011;117:3485-3493. 
47. Asosingh K, Aldred MA, Vasanji A, Drazba J, Sharp J, Farver C, Comhair SA, Xu W, Licina 
L, Huang L, Anand-Apte B, Yoder MC, Tuder RM, Erzurum SC. Circulating angiogenic 
precursors in idiopathic pulmonary arterial hypertension. Am J Pathol. 2008;172:615-627. 
 
48. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the 
pathogenesis of pulmonary arterial hypertension. Circ Res. 2014;115:165-175. 
 
49. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, 
van Rooijen N, Stenmark KR. Hypoxia-induced pulmonary vascular remodeling requires 
recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J 
Pathol. 2006;168:659-669. 
20. Karmouty-Quintana H, Philip K, Acero LF, Chen NY, Weng T, Molina JG, Luo F, Davies J, 
Le NB, Bunge I, Volcik KA, Le TT, Johnston RA, Xia Y, Eltzschig HK, and Blackburn MR. 
Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension. 
FASEB J. 2015;29:50-60. 
 
 
 
 
 
 
 
 
 
 at Imperial College London Library on May 12, 2016http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.116.021494 
23 
Clinical Perspective 
Pulmonary arterial hypertension (PAH) is a progressive fatal disease, which without treatment 
leads to right-heart failure and death often within 2-3 years of diagnosis. Owing to the poor 
understanding of the underlying mechanisms of obliterative vascular remodeling, current 
therapies result in only modest improvement in morbidity and mortality. One of the major 
hurdles is the lack of appropriate murine models recapitulating the pathophysiology of severe 
PAH in patients. In this study, we have demonstrated for the first time that genetic deletion of 
Egln1 in ECs and HCs induces spontaneous progressive PAH with severe pulmonary vascular 
remodeling including occlusion and complex plexiform-like lesions that resemble the pathology 
of clinical PAH. As seen in idiopathic PAH (IPAH) patients, Egln1Tie2 mice exhibit severe right 
ventricular hypertrophy and failure and progressive mortality. We also observed dysregulated 
expression of multiple PH-causing genes in Egln1Tie2 lungs. These complex pathological and 
molecular changes in Egln1Tie2 lungs are ascribed to HIF-2? activation. The severe PAH 
phenotype characterized with obliterative vascular remodeling and dysregulation of various 
signaling pathways as seen in clinical PAH makes the Egln1Tie2 mouse an unique and potentially 
useful mouse model for delineating the molecular mechanisms underlying the complex vascular 
remodeling of clinical PAH. The observation that PHD2 expression is diminished in ECs of 
obliterative pulmonary vessels of IPAH patients further demonstrates the clinical relevance of 
this model. Thus, targeting dysregulated PHD2/HIF-2? signaling may represent a novel effective 
therapeutic strategy to reverse pulmonary vascular remodeling for the treatment of severe PAH, 
including IPAH and promote survival. 
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Figure Legends: 
Figure 1. Spontaneous severe PAH in Egln1Tie2mice. (A-D) Tie2Cre-mediated disruption of 
Egln1 in lung ECs. A diagram showing the strategy for generation of Egln1Tie2 mice (A). 
Representative Western blotting demonstrating diminished PHD2 protein expression in EC lysate 
isolated from Egln1Tie2 lungs compared to WT (B). The experiment was repeated twice with 
similar data. QRT-PCR analysis demonstrating PHD2 deletion in Egln1Tie2 lung ECs but not in 
fibroblasts (Fib) (C). Data are expressed mean ±SD (n=3) (C). Representative micrographs of 
immunostaining showing EC-specific disruption of PHD2 in Egln1Tie2mouse lungs. Lung tissues 
were co-stained with anti-PHD2 and anti-CD31 (marker for ECs). Nuclei were counterstained 
with DAPI. PHD2 expression was diminished in pulmonary vascular ECs but not bronchial 
epithelial cells in Egln1Tie2 lungs. Please note the marked vascular remodeling in Egln1Tie2 lungs. 
Br, bronchiole; V, vessel. Scale bar, 50 ?m (D). CKO = Egln1Tie2. (E) Representative RVSP 
tracings (each=1 s). (F) Dramatic increase of RVSP in Egln1Tie2 mice. Bars represent the mean. 
(G) Marked RV hypertrophy in Egln1Tie2 mice. **, P < 0.01; ***, P < 0.001 (Student’s t test: C; 
Two-way ANOVA followed by Games-Howell post hoc analysis: F and G). 
 
Figure 2. Severe RV hypertrophy and failure and progressive mortality of Egln1Tie2 mice. (A) 
Representative echocardiography showing an enlarged RV chamber and thickened RV wall 
(hypertrophy) in Egln1Tie2 mice (3.5 mo old). (B-E) Echocardiography demonstrating enlarged 
RV chamber at end systole (ES) and end diastole (ED) (B); increased RV wall thickness diastole 
(RVWTD) (C); decreased RV fraction area change (RVFAC), indicative of decreased RV 
contractility (D); and a decreased PA AT/ET ratio (E) in Egln1Tie2 mice (3.5 months old). Data 
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are expressed as mean ± SD (n=5 WT and 6 Egln1Tie2). (F) QRT-PCR analysis demonstrating 
reactivation of an embryonic gene program in the right ventricles of Egln1Tie2 mice aged 3.5 mo, 
indicative of heart failure. ANF=Atrial natriuretic factor; sk-actin=skeletal ?-actin. (G). 
Progressive mortality of Egln1Tie2 mice. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Student’s t 
test (B-E), Welch t test (F) and log-rank (Mantel-Cox) test (G) were used for statistical analysis.  
 
Figure 3. Attenuated PAH in Egln1Tie2chimeric mice reconstituted with WT bone marrow cells. 
(A) A cartoon showing bone marrow (WT or CKO BM) transplantation to lethally irradiated WT 
mice. (B) QPCR analysis of Sry sequence (Y chromosome-specific gene) demonstrating greater 
than 95% efficiency of bone marrow reconstitution of female recipient WT mice with male 
Egln1Tie2 bone marrow. Bone marrow DNA from male WT mice was used as positive control. 
(C, D) Reconstitution of lethally irradiated WT mice with bone marrow cells from Egln1Tie2mice 
(CKO BM) had no effects on RVSP (C) and RV/LV+S ratio (D). As controls, WT bone marrow 
cells were also transplanted to WT recipient mice. (E-G) Egln1Tie2 chimeric mice reconstituted 
with WT bone marrow cells exhibited marked decreases of RVSP and RV hypertrophy. ***, P < 
0.001 (Student’s t test). CKO= Egln1Tie2. 
Figure 4. Occlusive pulmonary vascular remodeling in Egln1Tie2 mice. (A) Representative 
micrographs of Russel-Movat pentachrome staining demonstrating thickening of the intima, 
medial, and adventitial, occlusion of the large and small vessels (black arrowheads), and 
plexiform-like lesions (red arrowheads) in 3.5 mo old Egln1Tie2 mice (n=3 WT and 6 Egln1Tie2 
mice). Br, bronchus; V, vessel. Scale bar: 50 ?m. (B) Anti-CD31 immunohistochemistry 
showing multiple-channel lesions positive for the endothelial marker CD31 (arrows). Scale bar: 
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50 ?m. (C) Quantification of pulmonary vascular remodeling in Egln1Tie2 mice. Grade 1 (G1), 
medial hypertrophy; G2, medial hypertrophy and intimal thickening (partial occlusion); G3, 
occlusive lesions (>75% occlusion); G4, plexiform-like lesions. Much severe pulmonary 
vascular remodeling was identified in Egln1Tie2 mice at age of 3.5 mo compared to 1.5 mo. 
Total= all vessels quantified (n=280 vessels/group, n=5 mice/group). In 3.5 mo old Egln1Tie2 
mice, plexiform-like lesions (G4) were mainly seen in large vessels (>100 μm diameter) whereas 
occlusive lesions (G3) were prominent in small vessels. (D-F) Representative micrographs 
showing anti-smooth muscle ?-actin (?-SMA), anti-FSP1 or CD11b staining in pulmonary 
vascular lesions of Egln1Tie2 mice. . Br, bronchus; V, vessel. Scale bar, 50μm. (G) Representative 
micrographs showing proliferating ECs, SMCs and adventitial cells in pulmonary vascular 
lesions of Egln1Tie2 mice (3.5 mo old). Lung sections were immunostained with anti-Ki67 for cell 
proliferation and anti-CD31 for ECs. Arrowheads point to proliferating ECs; arrows indicate 
proliferating SMCs; open arrows denote proliferating adventitial cells. Scale bar, 50 μm. (H) 
Western blotting demonstrating increased expression of PCNA, a marker for cell proliferation in 
Egln1Tie2 lungs. 
Figure 5. Diminished PHD2 expression in occlusive pulmonary vessels of IPAH patients. (A) 
Immunostaining demonstrating diminished PHD2 expression (red) in the lumen of occlusive 
vessels (arrowheads) of IPAH lungs. Lung sections exhibited strong autofluorescence (AutoF) 
which helped to show the morphology. Arrows point to non-occlusive vessels; asterisk indicates 
blood cells. Scale bar, 50 μm. (B) Quantification of PHD2 expression. Immunofluorescent 
intensity (Fluo) was graded from 1 to 10 with 10 the highest. PHD2 expression was diminished 
in occlusive vessels of IPAH patients. Data are expressed as mean ± SD. **, P < 0.01 (Welch t 
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test). A.U., arbitrary units. 
Figure 6. Role of HIF-2? activation in Egln1Tie2 mice in mediating severe PAH. (A) Western 
blot showing stabilized HIF-1? and HIF-2? expression in Egln1Tie2 mouse lungs. The experiment 
was repeated twice with similar data. (B-D) Genetic deletion of HIF2? but not HIF1? in 
Egln1Tie2 mice completely normalized RVSP (C) and inhibited RV hypertrophy evident by 
normalized RV/LV+S ratio (2 months old). (D) Bars represent the mean. (E, F) 
Echocardiography demonstrating normalization of the RVWTD (E) and the PA AT/ET ratio (F) 
in EH2 mice at age of 3.5 months. Data are expressed as mean ± SD (n=6 WT, 8 Egln1Tie2 and 5 
EH2). (G) Russel-Movat pentachrome staining showed normal pulmonary vascular structure in 
EH2 mice at 3.5 month of age in contrast to Egln1Tie2 mice. Br, bronchiole; V, vessel. Scale bar: 
50 ?m. (H) Representative micrographs showing increased muscularization of distal pulmonary 
vessels (<50μm in diameter) in Egln1Tie2 mice and normalization in EH2 mice aged 3.5 months. 
Lung sections were immunostained with anti-smooth muscle ?-actin (SMA) (red). Arrows point 
to muscularized distal vessels. Scale bar, 50 ?m. (I) Quantification of muscularization. SMA– 
positive vessels were counted in 40 fields (×200) from each lung section. Data are expressed as 
mean ± SD (n=5 mice/group). *, P < 0.05; ***, P < 0.001. ANOVA followed by Games-Howell 
post hoc analysis was used for statistical analysis. 
 
Figure 7. Expression profiling of genes associated with various PH animal models. (A) 
Representative heat map of RNA-seq analysis in WT, Egln1Tie2 (CKO) and EH2 mouse lungs 
(n=3 mice/group). (B-D) RNA-seq analysis of HIF-? target genes (B), PH-causing genes (C, D) 
in mouse lungs. (E) Representative diagram showing increased Cxcl12 expression in Egln1Tie2 
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lungs whereas inhibited in EH2 lungs identified by RNA-seq analysis. (F) QRT-PCR analysis of 
expression of genes known upregulated in published PH animal models. Data are expressed as 
mean ± SD (n=4 WT, 6 CKO and 6 EH2). (G) QRT-PCR analysis of expression of genes known 
downregulated in PH animal models. *, P < 0.05; **, P < 0.01; ***, P < 0.001. ANOVA followed 
by Games-Howell post hoc analysis was used for statistical analysis. 
 
Figure 8. HIF-2?-mediated induction of CXCL12 in lung ECs induced SMC proliferation and 
contributed to severe PAH in Egln1Tie2 mice. (A) QRT-PCR analysis demonstrating HIF- 2?-
dependent induction of CXCL12 in PHD2-deficient ECs.  Small interfering RNAs specific for 
either PHD2, HIF1A, or HIF2A were transfected to human lung microvascular ECs. Scramble 
RNA against PHD2 was also transfected as a control. Data are expressed as mean ± SD (n=3). 
(B) Representative micrographs showing PHD2-deficient ECs induced SMC proliferation 
employing the Transwell co-culture system. Proliferating SMCs were immunostained with anti-
BrdU antibody (green). Scale bar, 50 μm. (C) Quantification showing PHD2-deficient ECs 
induced a marked increase of SMC proliferation which was partially inhibited by knockdown of 
CXCL12. n=3. (D) QRT-PCR analysis demonstrating siRNA- mediated knockdown of CXCL12 
in human lung ECs. (E) Cxcl12 expression was markedly induced in Egln1Tie2 (CKO) lungs in a 
HIF-2? but not HIF-1?-dependent manner. Lung tissues were collected from 1.5 mo old mice. 
(F) Generation of a mouse model with genetic deletions of both Egln1 and Cxcl12 (ECx). (G) 
ECx mice exhibited markedly decreased RVSP compared to CKO mice (3.5 mo old). (H) RV 
hypertrophy was also partially inhibited in ECx mice. **, P < 0.01; ***, P < 0.001. ANOVA 
followed by Games-Howell post hoc analysis was used for statistical analysis (A, C, E). 
Student’s t test was used for statistical analysis (D, G, H). (I) A diagram showing the model that 
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PHD2 deficiency in ECs and HCs induces obliterative pulmonary vascular remodeling and 
severe PAH. Endothelial PHD2 deficiency is essential for the development of PAH while PHD2 
deficiency in HCs promotes the severity of the disease. Through HIF-2? activation, PHD2 
deficiency induces dysregulation of multiple signaling pathways in mouse lungs which may act 
together to induce severe pulmonary vascular remodeling including vascular occlusion and 
formation of plexiform-like lesions as well as vasoconstriction and thereby severe PAH and RV 
failure. 
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ONLINE METHODS 
 
Echocardiography. Echocardiography was carried out in the Cardiovascular Physiology Core at 
the University of Illinois at Chicago Research Resources Center.1 Transthoracic 
echocardiography was performed on a VisualSonics Vevo 2100 ultrasound machine (FujiFilm 
VisualSonics Inc) using an MS550D (40 MHz) transducer. Results were calculated using 
VisualSonics Vevo 2100 analysis software (v. 1.6) with a cardiac measurements package and 
were based on the average of at least three cardiac cycles. Briefly, mice were anesthetized in an 
induction chamber filled with 3.5% isoflurane mixed with 100% oxygen and then placed in a 
supine position on a heated stage containing ECG leads. The heated stage also contained a 
nosecone filled with 1.5% isoflurane in 100% oxygen delivered at 1.0 L/min and an anal 
temperature probe by which temperature was maintained at 37°C. A chemical hair remover was 
used to remove the fur on the chest of the mice. The left ventricle anterior/posterior wall 
thickness during diastole (LVAW and LVPW), the LV internal dimension during diastole 
(LVID), the LV fractional shortening (LV FS) and the cardiac output (CO) were obtained from 
the parasternal short axis view using M-mode. The right ventricle wall thickness during diastole 
(RVWTD) and the RV cross-sectional area were obtained from the parasternal short axis view at 
the papillary muscle level using M-mode. Pulmonary artery (PA) acceleration time and PA 
ejection time were obtained from the parasternal short axis view at the aortic valve level using 
pulsed Doppler mode. All measurements were taken in compliance with the American Society of 
Echocardiography guidelines. 
RV hemodynamic measurements. RVSP was measured with a 1.4F pressure transducer 
catheter (Millar Instruments) and AcqKnowledge software (Biopac Systems Inc.) as described 
previously.1,2 Briefly, the catheter was inserted through the right jugular vein into the right 
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ventricle in anesthetized mice (100 mg ketamine/5 mg xylazine /kg body weight, i.p.). RVSP 
was recorded and analyzed with AcqKnowledge software (Biopac Systems Inc.). 
Irradiation and Bone marrow transplantation. WT or Egln1Tie2 female mice at the age of 3 
weeks were delivered at a dose of 750 cGy/mouse. At 3 hours following irradiation, mice were 
transplanted with 1×107 bone marrow cells (in 150 µl of HBSS) isolated from male Egln1Tie2  or 
WT mice through tail vein injection.3 Mice were used for RVSP measurement and tissue 
collection at the age of 3.5 mo. To determine the efficacy of bone marrow cells reconstitution, 
bone marrow cells were isolated from the chimeric mice after RVSP measurement. Genomic 
DNA was extracted and used for QPCR analysis of Sry gene (a male-specific gene) as describe 
previously.4 Autosomal gene Nme1 was used for internal control.  
Primary cultures of human lung microvascular ECs and pulmonary arterial SMCs. 
Primary HMVEC-L cells (Lonza) were cultured as describe previously.5 Briefly, HMVEC-L 
cells were cultured in T75 flasks precoated with 0.2% gelatin in EBM-2 medium supplemented 
with 15% FBS and EGM-2 MV Singlequots (Lonza), and maintained at 37? in a humidified 
atmosphere of 5% CO2. Cells between passage 4 and 7 were used for experiments. Primary 
human PASMCs (Lonza) were cultured in T75 flasks in SmGM-2 medium supplemented with 
5%FBS and SmGM-2 SingleQuots (Lonza) under 5% CO2 incubator. PASMCs were used for 
experiments between 3 and 6 passages. 
siRNA-mediated gene knockdown. HIF-1α siRNA was synthesized (Integrated DNA 
Technology) according to previous publication.6 The other siRNA for EGLN1 (SI04188212), 
HIF2A (SI02663038) and CXCL12 (SI03649100) were obtained from Qiagen. Transfection of 
siRNA was performed using HMVEC-L Nucleofector kit (Lonza) with the Amaxa Nucleofector 
device (Lonza).5 
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ECs and SMCs co-culture and cell proliferation analysis. PASMCs were seeded in 6 well 
plate overnight and starved with 0.2% FBS for 16 hours. HMVEC-L cells after siRNA or 
scramble RNA transfection were seeded in the insert of Transwell system. Thirty-six hours post 
transfection, HMVEC-L cells in the Transwell insert were placed on the top of PASMC for co-
culture for 16h. To access PASMC proliferation, 5-bromo-20 -deoxyuridine (BrdU, Sigma) was 
added at 10 µmole/L in the lower compartment. Cells were stained with anti-BrdU-FITC (BD 
bioscience, cat#347583) according to the manufacturer’s instruction and nuclei were 
counterstained with DAPI. 
RNA isolation and QRT-PCR analysis. Total RNA was isolated from frozen mouse lung 
tissues with Trizol reagents (Invitrogen) followed by purification with the RNeasy Mini kit 
including DNase I digestion (Qiagen). RNA from mouse and human cells were directly isolated 
with the RNeasy mini kit. One microgram of RNA was transcribed into cDNA using the high-
capacity cDNA reverse transcription kits (Applied Biosystems) according to the manufacturer’s 
protocol. Quantitative RT-PCR analysis was performed on an ABI ViiA 7 Real-time PCR system 
(Applied Biosystems) with the FastStart SYBR Green Master kit (Roche Applied Science). 
Target mRNA was determined using the comparative cycle threshold method of relative 
quantitation. Cyclophilin was used as an internal control for analysis of expression of mouse 
genes 3 while 18s rRNA gene was used for human genes. The primer sequences are provided in 
Supplemental Table 1. 
Western blot analysis. Lung tissue samples from mice were homogenized in RIPA lysis buffer 
(Cell Signaling Technology) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF) 
and protease inhibitor cocktails (Sigma). Western blot analysis was performed using anti-PHD2 
(1:2000, Cell Signaling Technology, Cat#4835), HIF-1α (1:1000, Cell Signaling Technology, 
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Cat #14179), HIF-2α (1:500, Novus Biologicals, Cat#NB100-122) and PCNA (1:200, Santa 
Cruz, Cat#sc-56). Anti-β-actin (1:10,000, Sigma-Aldrich，Cat#A2228) was used as a loading 
control. 
Immunofluorescent staining, immunohistochemistry and histological assessment of 
pulmonary vascular remodeling. Following PBS perfusion, lung tissue was embedded in OCT 
for cryosectioning for immunofluorescent staining or fixed with 10% formalin for histological 
analyses including Russel-Movat pentachrome staining and immunohistochemistry with anti-
CD31 antibody (1:40, Abcam, Cat#ab28364). Briefly, the left lobe of lung tissue was perfused 
with 50% OCT through tracheal catheterization, and then embedded in OCT for cryosectioning. 
Lung sections (5 μm) were fixed with 4% paraformaldehyde, followed by blocking with 0.1% 
Triton X-100 and 5% normal goat serum at room temperature for 1 h. After 3 washes, they were 
incubated with anti-PHD2 antibody (1:200, Cell Signaling Technology, Cat#4835), anti-Ki67 
(1:25, Abcam, Cat#ab1667), anti-CD31 antibody (1:25, BD Biosciences, Cat#550274), anti-
FSP1 (1:500, Abcam, Cat#27957), and anti-CD11b (1:200, BD Biosciences, Cat#557394) at 4? 
overnight and were then incubated with either Alexa 647-conjugated anti-rabbit IgG (Life 
Technology), or Alexa 594-conjugated anti-rabbit IgG or Alexa 488 conjugated anti-rat IgG at 
room temperature for 1 h after 3 washes. Nuclei were counterstained with DAPI contained in 
Prolong Gold mounting media (Life Technology).  
 For immunohistochemistry and histology, mouse lungs were fixed for 5 min by instillation 
of 10% PBS-buffered formalin through trachea catheterization at a transpulmonary pressure of 
15 cm H2O, and then overnight at 4oC with agitation. After paraffin processing, the tissues were 
cut into semi-thin 5 m thick sections. Mouse lung sections were then dewaxed and dehydrated. 
Antigen retrieval was performed by boiling the slides in 10 mmol/L sodium citrate (pH 6.0) for 
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10 minutes. After blocking, slides were incubated with anti-α-smooth muscle actin (α-SMA, 
1:300, Abcam, Cat#ab5694) or anti-CD31 (1:40, Abcam, Cat#ab28364) at 4oC overnight and 
were then incubated with Alexa 594 conjugated anti-rabbit IgG at room temperature for 1 h. The 
nuclei were counterstained with DAPI. The same procedure was applied to immunostaining of 
PHD2 in formalin-fixed lung sections from IPAH patients and control donors. Anti-PHD2 (1:200, 
Cell Signaling Technology, Cat#4835) was incubated at 4oC overnight followed by incubation 
with Cy5-conjugated secondary antibody (1:100, Jackson ImmunoResearch). 
 For immunohistochemistry, slides were incubated with 6% H2O2 for 30 min after primary 
antibody incubation and were then biotinylated with a rabbit IgG and ABC kit (Vector Labs) for 
immunohistochemistry. The nucleus was co-stained with hematoxylin (Sigma-Aldrich).  
 For assessment of vascular remodeling, paraffin sections of mouse lungs were dewaxed 
and dehydrated, and then stained with a Russel-Movat pentachrome staining kit (American 
MasterTech) according to the manufacturer’s protocol.7,8 
RNA sequencing and bioinformatics analysis. RNA sequencing was carried out at the 
University of Chicago Genomics Facility. Briefly, RNA quality was checked on an Agilent Bio-
analyzer. RNA-seq libraries were generated with TruSeq® Stranded Total RNA LT -(with Ribo-
Zero), RS-122-2301. All samples were sequenced with an Illumina Hiseq2500 with a single end 
50-bp read length. For bioinformatics analysis, raw reads were trimmed to minimum Q20 using 
trimmomatic.9 An initial alignment against mouse rRNA sequences using bowtie2 to remove any 
remaining ribosomal sequences was performed. We aligned the remaining reads with TopHat2 10 
against the reference genome plus the transcriptome sequence by using UCSC Refseq 
annotations. Per-gene expression was quantified using CuffNorm 11 and the differential 
expression, fold-changes, p-values, and q-values between conditions using CuffDiff were 
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computed.  
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Supplemental Table 1. Primer sequences used for QRT-PCR analysis. 
Gene name Forward primer Reverse primer 
Acrv2b ACGACTTTGTGGCTGTGAAGA ACTGCAACAAGTTTTCGTGCT 
Acrvl1 GCAAAACGTGATAGCTGTGGT GCAAAACGTGATAGCTGTGGT 
ANF TATCTCAAGCTGCTTTGGGCA GCCAGGAGGTCTTCCTACAAC 
Apln TCGTGGTGCTTGTAGTGACC ATGCAGGTGCAGTACGGAAA 
Aplnr GACCGAGTTGCAGCATGAATC ATCTGGAGGCAACATCAGTGG 
Bmpr2 AAGAGCACAGAGGCCCAATTC CCATCTTGTGTTGACTCACCT 
Cav1 GACCCCAAGCATCTCAACGA TTGGGATGCCGAAGATCGTA 
Ccr2 GTTCAGCTGCCTGCAAAGAC ATGCCGTGGATGAACTGAGG 
Ccr7 ACCAAAAGCACAGCCTTCCT GAAGCACACCGACTCGTACA 
Csf2 ACCTCCTGGATGACATGCCT GTTTGGTGAAATTGCCCCGT 
Cxcl12 CCAAGAGTACCTGGAGAAAGC AGTTACAAAGCGCCAGAGCA 
Edn TTCCCAATAAGGCCACAGACC TTGGGCCCTGAGTTCTTTTCC 
Egln1 CGGCGTAACCCTCATGAAGTA TTTAGCTCTCGCTCGCTCATC 
Eln GGCGTCTTGCTGATCCTCTT GAACTCCACCAGGAAGTCCG 
Fgf2 TGAAGGAAGATGGACGGCTG ACTGCCCAGTTCGTTTCAGT 
Foxo1 AGTGGATGGTGAAGAGCGTG GAAGGGACAGATTGTGGCGA 
Grem1 GGCTCCTTGGGAACCTTTCTTT GGCTCCTTGGGAACCTTTCTTT 
Il6 GGATACCACTCCCAACAGACC CTGCAAGTGCATCATCGTTGT 
Nme1 ACAGCTCTGCATTCCTTACC AGAACAGAACACAGGTGATAGG 
Notch3 TGAACAACGTGGAGGCTACC GCAGCCTGTCCAAGTGATCT 
Prkg1 CCAACATTCCAGAGCCTTCCT TCGAGTAACATTCACCTGCCC 
Serpine1 AGTCTTTCCGACCAAGAGCAG GATGACAAAGGCTGTGGAGGA 
Sk-α-actin TCCAAGTCCTGCAAGTGAACA CTTCGTCGCACATGGTGTCTA 
Slc39a12 ACCATCCAACTGAAAGGCCC TGTGCAGGCTATCTCCAACC 
Sphk1 CCCAAACCGGTTCAGCTTTC TTATCGGTGTTGCCCAGGAG 
Sry GCTGGGATGCAGGTGGAAAA CCCTCCGATGAGGCTGATATT 
h18s rRNA TTCCGACCATAAACGATGCCGA GACTTTGGTTTCCCGGAAGCTG 
hCXCL12 AACTGTGCCCTTCAGATTGTAG TCGAGTGGGTCTAGCGGAAAGT 
hHIF1A TTACAGCAGCCAGACGATCATG TGGTCAGCTGTGGTAATCCACT 
hHIF2A CTGATGGCCATGAACAGCATCT TCCTCGAAGTTCTGATTCCCGA 
hEGLN1 TTTTCTGGTCTGACCGTCGC CCTCACACCTTTTTCACCTGT 
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Supplementary Figures and Figure Legends 
 
Supplementary Figure 1. Normal systemic blood pressure in Egln1Tie2 mice. (A) 
Representative micrographs demonstrating efficient deletion of PHD2 in descending aortic 
vascular ECs of Egln1Tie2 mice. Please note the prominent expression of PHD2 in the media 
(smooth muscle cells) and weak expression in ECs in WT mice. CKO= Egln1Tie2. (B) Systolic 
and diastolic blood pressure measured by tail cuff from WT and Egln1Tie2 mice at 2 mo of age. 
Data are expressed as mean ± SD (n=4WT, 6Egln1Tie2 mice). (C) QRT-PCR analysis 
demonstrating little changes of expression of Cxcl12 and Edn1 (encoding Endothelin-1) in 
mouse aorta, which is in sharp contrast in the marked induction of these genes in Egln1Tie2 mouse 
lungs. Student t test was used for statistical analysis (B and C). 
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Supplementary Figure 2. Echocardiography of LV chamber size and function. At 1.5 mo of 
age, Egln1Tie2 mice (CKO) mice exhibited similar LV anterior wall diastole (LV AWd) (A) and 
systole (LV AWs) (B), and LV internal diameter diastole (LV IDd) (C) and systole （LV IDs） 
(D), LV fraction shortening (LV FS) (E) and cardiac output (CO) (F) to WT mice.(n=4 per 
group). Student t test was used for statistical analysis. 
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Supplementary Figure 3. Representative micrographs of Russel-Movat pentachrome staining 
showing attenuated pulmonary vascular remodeling in of Egln1Tie2 chimeric mice 
reconstituted with WT bone marrow cells. Bone marrow cells isolated from WT or Egln1Tie2 
(CKO) mice were transplanted to lethally irradiated Egln1Tie2 mice. Three month later, lungs 
were collected for pathological analysis. Adventitial and neointimal remodeling Egln1Tie2 
chimeric mice was attenuated but medial thickness was not markedly different from Egln1Tie2 
mice reconstituted with Egln1Tie2 bone marrow cells. Br, bronchus. Scale bar, 50µm. 
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Supplementary Figure 4. Severe pulmonary vascular remodeling in Egln1Tie2 mice. (A-H) 
Representative micrographs of Russel-Movat pentachrome staining showing thickening of the 
media (A), intima (B), and adventitia (C), occlusion of large and small vessels (D-F, 
arrowheads), and various forms of complex plexiform-like lesions including stalk-like and 
aneurysm-like lesions (F-H, arrows) in lungs of Egln1Tie2 mice aged 3.5 months. (I, J) 
Representative micrographs of anti-CD31 immunohistochemistry of lung sections. CD31 
immunostaining was prominent in non-occlusive vessels but diminished in occluded vessels 
(arrows). Br, bronchus. Scale bar, 50 μm.  
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Supplementary Figure 5. HIF-2 deletion in Egln1Tie2 mice completely rescued PAH 
phenotype. (A) Western blot demonstrating increased HIF-2 expression in EC lysates of 
Egln1Tie2 (CKO) mouse lungs and diminished in Egln1Tie2/Hif2aTie2 (EH2) mouse lungs. (B-C) 
Deletion of HIF-2α in Egln1Tie2 mice normalized RVSP (aged 3.5 mo) (B) and inhibited RV 
hypertrophy as evident by normalized RV/LV+S ratio (aged 3.5 mo) (C). Bars represent the 
mean. ***, P < 0.001. ANOVA followed by Games-Howell post hoc analysis was used for 
statistical analysis. 
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